Advanced Therapy Medicinal Products (ATMPs) which include CAR T-cell therapies, will be some of the first products to undergo assessment through the new EU HTA Regulation process from January 2025. Understanding the evidence requirements and implications on decision outcomes is imperative for future reimbursement success in Europe. Discover additional insights on CAR T-cell reimbursement in the US, UK and EU4 in our whitepaper: https://buff.ly/4eFtDkM #LumanityPerspectives #HEOR #Oncology #Reimbursement #EUHTARegulation
Lumanity Value, Access & Outcomes’ Post
More Relevant Posts
-
Advanced Therapy Medicinal Products (ATMPs) which include CAR T-cell therapies, will be some of the first products to undergo assessment through the new EU HTA Regulation process from January 2025. Understanding the evidence requirements and implications on decision outcomes is imperative for future reimbursement success in Europe. Discover additional insights on CAR T-cell reimbursement in the US, UK and EU4 in our whitepaper: https://buff.ly/48i2wc9 #LumanityPerspectives #HEOR #Oncology #Reimbursement #EUHTARegulation
-
Advanced Therapy Medicinal Products (ATMPs) which include CAR T-cell therapies, will be some of the first products to undergo assessment through the new EU HTA Regulation process from January 2025. Understanding the evidence requirements and implications on decision outcomes is imperative for future reimbursement success in Europe. Discover additional insights on CAR T-cell reimbursement in the US, UK and EU4 in our whitepaper: https://buff.ly/3HfYvZq #LumanityPerspectives #HEOR #Oncology #Reimbursement #EUHTARegulation
CAR T-Cell Therapies in the US, UK and EU4
-
Advanced Therapy Medicinal Products (ATMPs) which include CAR T-cell therapies, will be some of the first products to undergo assessment through the new EU HTA Regulation process from January 2025. Understanding the evidence requirements and implications on decision outcomes is imperative for future reimbursement success in Europe. Discover additional insights on CAR T-cell reimbursement in the US, UK and EU4 in our whitepaper: https://buff.ly/4dHJ2ke #LumanityPerspectives #HEOR #Oncology #Reimbursement #EUHTARegulation
-
-
Read Abby Mallon's article in BioPharma Dive https://lnkd.in/gkNwJGx4 to see how #NurseNavigators and #ClinicalNurseEducators can improve #MedicationAdherence and #PatientEngagement in the oncology space – particularly as more oral therapeutics enter the market.
-
-
Apropos of my comments at the #StatBreakthrough Summit a few weeks ago, access without answers serves no one except the bottom line of pharmaceutical companies. We've created an incentive structure that gets drugs out there, drugs we know less and less about, pay more and more for, and then we're surprised when this happens? #StatNews #StatSummit.
Haematology Registrar at Peter Mac & RMH interested in lymphoid malignancies, immunotherapies, clinical trials and health policy
Delighted to present our work at #AACR24 today, led by Ian Liu, on oncology accelerated approvals, simultaneously published in JAMA Accelerated approval is a useful program but has a long way to go to ensure it delivers high-value drugs You can check out the article (and an information-packed supplement) here: https://lnkd.in/gCFqv94n Program on Regulation, Therapeutics, and Law (PORTAL) Aaron S. Kesselheim, M.D., J.D., M.P.H. Brigham and Women's Hospital Harvard Medical School AACR Journals JAMA JAMA Oncology
-
-
DID YOU KNOW? Drug development programs with clinical trials employing patient preselection biomarkers have a two-fold higher likelihood of approvals (15.9%), driven by a Phase II success rate of nearly one-in-two.[1] Learn more about how CertisAI™ Predictive Oncology Intelligence can be used to develop stratification strategies for clinical trial patient selection: https://hubs.la/Q01-jZQ90. #AI #ArtificialIntelligence #MachineLearning #PredictiveAnalytics #DigitalDrugDevelopment #PersonalizedMedicine #CancerResearch #TranslationalScience #FightCancer #EndCancer #CertaintyisPriceless [1] Clinical Development Success Rates and Contributing Factors 2011–2020. BIO. Feb. 2021:17-18. Figure: Chart of phase transition success rates and LOA from Phase I.
-
-
Oncology Devices Global Market Report The oncology devices market size is expected to see rapid growth in the next few years. It will grow to $298.31 billion in 2028 at a compound annual growth rate (CAGR) of 18.0% https://lnkd.in/eYBCVNwh #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel
-
Do you need help with the strategic use of your clinical data? 🧑🏼💻🩺 At ZEMA Pharma Consulting we can be your strategic partner that helps you use clinical data strategically. We help you with how you collect and interpret data within oncology and hematology. We help you turn these data into a strategy ensuring access of your medicines to patients with an unmet need. #ZEMAPharmaConsulting #ClinicalData #MedicalStrategy
-
-
October is #BreastCancer Awareness Month, so why not explore FREE #oncology resources on #Medthority? Access clinical trial data, congress highlights, key developments in treatment and more. For #healthcareprofessionals only. ➡️ https://ow.ly/rJ9a50PLtBN #CME #HCP #MedicalEducation #MedEd #BreastCancerAwareness #CPD #eLearning Content developed independently of sponsors, Sandoz, Eli Lilly & AstraZeneca
-
Head - Business Development | Clinical Trials | Clinical Research Services (Early, Late Phase, Post Approval) | Pharma-Biotech-Medical Devices.
Clinfinite Solutions with 25+ Years of Experience and 100+ Clinical/Device Studies #oncology #oncologyresearch #oncologytrials #clinical #medtech #medicaldevices #pharma #biotech #consumerhealth #clinicaltrials #regulatory #datamanagement #medicalwriting #biorepository #biospecimen #biobanking
